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Edited by Robert BaroukiAbstract A number of human diseases can be linked to aberra-
tions in protein folding which cause an imbalance in protein
homeostasis. Molecular chaperones, including heat shock pro-
teins, act to assist protein folding, stability and activity in the
cell. Attention has begun to focus on modulating the expression
and/or activity of this group of proteins for the treatment of a
wide variety of human diseases. This review will describe the pro-
gress made to date in developing pharmacological modulators of
the heat shock response, including both agents which aﬀect the
entire heat shock response and those that speciﬁcally target
the HSP70 and HSP90 chaperone families.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Inhibitor1. Introduction: heat shock proteins in health and disease
Protein synthesis in vivo is supported by molecular chaper-
ones which assist the folding of nascent polypeptides, avoid
the formation of aggregates by preventing non-speciﬁc interac-
tions and aid the translocation of proteins to their correct
intracellular localization. When a protein is damaged, molecu-
lar chaperones may also facilitate their re-folding or, in the
case of irreparably impaired proteins, their removal by the pro-
tein degradation machinery of the cell [1].
Heat shock proteins (HSPs) were originally deﬁned accord-
ing to their increased expression in response to a cellular insult
such as elevated temperature, heavy metals and oxidative stress
[1]. Most, but not all HSPs are molecular chaperones that are
organized into families according to their molecular size or
function, including HSP100, HSP90, HSP70, HSP60, HSP40
and small HSPs. The often rapid induction of HSP gene
expression in response to stress is a result of a coordinated ser-
ies of biochemical and genetic events which are collectivelyAbbreviations: 17-AAG, 17-allylamino-17-demethoxygeldanamycin;
17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamy-
cin; HSP, heat shock protein; HSR, heat shock response; TPR,
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doi:10.1016/j.febslet.2007.05.040referred to as the heat shock response (HSR). Activation of
the HSR results in cytoprotection to repeat exposure of the ini-
tial insult which would otherwise cause lethal molecular dam-
age [2].
Cytoprotection is an example of increased molecular chaper-
one expression associated with the functioning of normal cells.
However, aberrant expression of this family of proteins can
also be associated with several disease states. There is increas-
ing evidence associating molecular chaperone expression with
neurodegenerative disorders including Parkinson’s, Alzhei-
mer’s, Huntington’s and prion-related disease [3,4]. Also a
large body of evidence supports the role of molecular chaper-
ones in maintaining the cancer phenotype [5–7]. This present
review will focus on the current eﬀorts to modulate the expres-
sion and activity of molecular chaperones as a novel approach
to treat protein-folding diseases, with a particular emphasis on
the treatment of cancer.2. Modulation of HSF1 and the HSR
The HSR is mediated at the transcriptional level by heat
shock factors (HSFs), a group of transcription factors that
are capable of speciﬁcally binding to heat shock elements with-
in the promoter of HSP genes [8]. Among the three human
HSF genes, HSF-1, -2 and -4, HSF1 is essential for the regula-
tion of HSP expression in response to stress [8]. Although the
other HSFs may contribute to the activity of HSF1, this review
will focus on the regulation and modulation of HSF1 activity.
The activity of HSF1 is dependent on its ability to bind
DNA, which is achieved via a series of modiﬁcation steps de-
scribed in Fig. 1. Through the propensity of HSF1 to control
the expression of a number of diﬀerent HSPs, an increasing
amount of interest has focused on the development of small-
molecule modulators which can alter the activity of HSF1
[2]. This may be of therapeutic beneﬁt in the treatment of dis-
eases which have an underlying abnormality in protein confor-
mation or activity. So far several, structurally unrelated
compounds have been identiﬁed which can induce or inhibit
the HSR.2.1. HSR inducers
There are various agents which induce the HSR and
promote HSP expression without the requirement for
additional forms of stress such as heat shock. These
agents could have a therapeutic application in the treatmentblished by Elsevier B.V. All rights reserved.
Fig. 1. Activation and modulation of HSF1 transcriptional activity (a) Under normal conditions HSF1 exists as a monomer held in a repressed state
by an interaction with HSP90 and HSP70. (b) Cellular stress causes an increase in denatured proteins (c) which leads to the dissociation of HSP90
and HSP70 from HSF1. (d) Monomeric HSF1 is then free to trimerize, translocate to the nucleus and (e) undergo a series of post-translational
phosphorylation events. (f) HSF1 activates the transcription of a number of HSP genes, including HSP90 and HSP70. (g) The increased cellular
concentration of these chaperones can then inactivate HSF1 by binding to monomeric or trimeric forms of the transcription factor (reviewed in [2,8]).
Also shown are the chemical structures of a selection of HSF1 modulators.
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creased chaperone expression to reduce the levels of misfolded
or aggregated proteins that underlie the development of the
pathological condition [2]. Proteasome inhibitors including
MG-132, lactacystin and bortezomib, the latter clinically ap-
proved for treatment of multiple myeloma [9], activate the
HSR [10,11]. This response is proposed to be a consequence
of increasing the intracellular concentration of misfolded pro-
teins which in turn cause the dissociation of HSF1 from its
repressive complex with HSP90 and HSP70 [2]. Subsequently,
proteasome inhibitors induce hyperphosphorylation of HSF1,
DNA binding, and increased expression of HSPs [10].
The HSR can also be activated by molecules that regulate
inﬂammation [2]. The inﬂammatory response involves the
sequential activation of various signaling molecules, among
which arachidonic acid and its metabolites such as prostaglan-
dins play a crucial role. Phospholipase A2 stimulates the
release and metabolism of arachidonic acid. Both phospholi-
pase A2 and arachidonate induce the heat shock response by
promoting increased DNA-binding by HSF1 [12]. Cyclopente-
none prostaglandins of the A and J type also activate HSF1
and increase the expression of HSP70 [13].
A novel inducer of the HSR has recently been identiﬁed [14].
Terrecyclic acid A (TCA) perturbs the redox state of the cell
and increases the levels of reactive oxygen species [14]. Oxida-
tive stress, similar to thermal stress, requires the rapid and
adaptive increase in HSP synthesis; therefore, the increased
levels of reactive oxygen species leads to the activation of
HSF1 [14].
Several inhibitors of HSP90 stimulate the activity of HSF1.
The mechanism of action of these compounds, which include
radicicol and the benzoquinone ansamycins, is described in
more detail later in this review. They induce the HSR by stim-
ulating the dissociation of HSF1 from its repressive complex
with HSP90 [15]. This results in the increased expression of a
wide range of HSPs including HSP90, HSP70 and HSP27[16,17]. The exact mechanism underlying the dissociation of
HSF1 from HSP90 in response to its inhibition by these agents
has not been clearly established. However, it is proposed that
inhibition of HSP90 function may, in a similar fashion to pro-
teasome inhibitors, alter protein homeostasis by increasing the
concentration of denatured proteins which compete with
HSP90 for HSF1 interaction, thereby increasing the amount
of active HSF1 [15].
HSF1 can also be activated by the natural triterpene, celas-
trol (Fig. 1). Exposure of cells to this compound induced the
expression of HSP70, HSP40 and HSP27 by promoting the
hyperphosphorylation, DNA binding, and transcriptional
activity of HSF1 with kinetics similar to those observed fol-
lowing heat shock [18]. The mechanism by which celastrol in-
duces HSF1 activity has not been clearly deﬁned. It has been
shown to have no direct activity on the chaperone function
of HSP70 nor does it cause global protein denaturation [18].
However, celastrol potently inhibits the chymotrypsin-like
activity of puriﬁed 20S proteasome [19]. In addition, celastrol
and the structurally related triterpene, gedunin, have been re-
cently proposed as novel HSP90 inhibitors (see later and
[20]). Both of these observations may begin to explain how cel-
astrol induces the HSR; however, further investigations are re-
quired to determine its exact mechanism of action.
All of the above compounds can act independently to aﬀect
the activity of HSF1; however, there is a class of compounds
referred to as ‘co-inducers’ which are able to activate an en-
hanced HSR in synergy with low levels of cellular stress [2].
Non-steroidal anti-inﬂammatory drugs (NSAIDS), including
aspirin, indomethacin and sodium salicylate act as co-inducers
by stimulating the trimerization of HSF1 and reducing the
temperature required for complete activation of the transcrip-
tion factor [21]. Other chaperone co-inducers are the non-toxic
hydroxylamine derivatives bimoclomal and arimoclomal.
Bimoclomal binds to HSF1 with low aﬃnity to prolong the
duration of HSF1 binding to DNA and has shown promise
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wound healing [22]. This is postulated to be a result of the
coordinated expression of all major HSPs which occur as a re-
sult of HSF1 induction [22].2.2. HSR inhibitors
Inhibitors of the HSR may be of particular beneﬁt for the
treatment of cancer because tumor cells typically express high-
er levels of HSPs than normal cells and indeed may be more
dependent on HSPs than normal cells. This may be a conse-
quence of the hostile conditions created in tumor cells by the
eﬀects of deregulated oncogenes or tumor suppressor genes,
along with the stressful microenvironmental features of solid
tumors, which include nutrient deprivation, hypoxia and aci-
dosis [5,7]. The increased expression of HSPs not only likely al-
lows the cells to tolerate cumulative mutations and aberrant
protein expression which may be otherwise lethal, but may also
promote tumor cell survival via the well-documented anti-
apoptotic function of HSPs [23]. In addition to promoting tu-
mor cell survival, induction of the HSR may reduce the eﬃcacy
of existing anti-cancer strategies, which are complicated by the
concurrent induction of this anti-apoptotic response. Studies
using siRNA to target HSF1 have reinforced the potential va-
lue of developing chemical modulators of the HSR by demon-
strating increased sensitization to heat shock, proteasome
inhibitors, HSP90 modulators and hyperthermo-chemother-
apy when HSF1 expression is reduced [24,25].
The naturally occurring ﬂavonoid, quercetin (3,3 0,4 0,5,7-pen-
tahydroxyﬂavone, Fig. 1) inhibits the heat-induced expression
of HSPs in a range of diﬀerent cell types by aﬀecting several
aspects of HSF1 activity, including HSF1 hyperphosphoryla-
tion, DNA binding and ultimately transcriptional activity
[26]. Treatment with quercetin inhibits the growth of cancer
cells both in vitro and in vivo, and also demonstrates evidence
of tumor cell versus normal cell selectivity [27]. Quercetin pre-
treatment also renders cells more susceptible to apoptotic stim-
uli, including hyperthermia and chemotherapy [28]. However,
the activity of quercetin is not speciﬁc because it not only mod-
ulates HSF1 activity but also inhibits the activity of several
protein kinases [29,30].
Compounds which appear to inhibit HSP expression more
speciﬁcally and eﬀectively than quercetin are currently being
investigated and include the benzylidene lactam, KNK437
(Fig. 1). This compound can inhibit the heat-induced expres-
sion of a variety of HSPs including HSP110/HSP105, HSP72
and HSP40 [31], but has no eﬀect on the expression of consti-
tutively expressed HSP family members including HSC70 and
HSP90 [31]. KNK437 inhibits thermotolerance both in vitro
and in vivo, resulting in increased response to hyperthermia,
low dose-rate irradiation and the HSP90 inhibitor 17-AAG
(see later and [32,33]). Unlike quercetin, KNK437 does not in-
duce signiﬁcant toxicity when administered alone [31] which
may be because, unlike quercetin, KNK437 does not have a
pleiotropic eﬀect on protein kinase activity [31]. Although both
quercetin and KNK437 have been shown to have an eﬀect on
HSF1 activity, the exact mechanism by which they prevent the
acquisition of thermotolerance is not known and remains to be
elucidated.
Despite their potential in vitro, quercetin and KNK437 may
not be suﬃciently potent for clinical use as high concentrations
of compound are required to demonstrate inhibitory activity(100–500 lM). Use of such high concentrations of low potency
agents increases the likelihood of oﬀ-target eﬀects. A promis-
ing alternative to quercetin and KNK437 has recently been
identiﬁed as part of a small-molecule high throughput screen
for modulators of the HSR [34]. The diterpene triepoxide tri-
ptolide (Fig. 1) potently inhibits the heat shock induction of
HSP70 expression by a novel mechanism which does not in-
volve inhibition of HSF1 trimer formation, HSF1 hyper-
phosphorylation or the nuclear translocation and binding of
HSF1 to the HSP70 gene promoter [34]. Instead, triptolide
inhibits HSP expression by interfering with the activity of
the C-terminal transactivation domain of HSF1 and blocking
its transcriptional activity [34]. Treatment with triptolide alone
was shown to signiﬁcantly inhibit cytoprotection and enhance
lethality when used prior to heat shock [34]. Similar to querce-
tin, triptolide can also modulate the activity of other cellular
proteins including the transcription factors NF-jB and AP-1
[35].
Two novel inhibitors of the HSR, NZ28 and emunin, have
recently been identiﬁed by a two-step high-throughput screen
which utilized a cell-based luciferase refolding assay in the
ﬁrst step, followed by a counterscreen for toxicity [24].
Although slight inhibition of HSF1 activity was seen after
treatment with both compounds it was postulated that their
predominant mechanism of action was at the post-transcrip-
tional level [24].
Because of their eﬀects on modulating molecular chaperone
expression, HSR inhibitors exhibit considerable potential as
anticancer agents for use in combination with existing cancer
treatments, such as hyperthemia, which are compromised by
the concommitant induction of the HSR. Proof-of-concept
for this strategy has been demonstrated using quercetin pre-
treatment to potently amplify the eﬀects of hyperthermia in
two human prostate tumor models in vivo [36]. Potency and
selectivity are properties that need to be optimized to allow
agents to be taken forward for clinical development.3. Direct modulators of molecular chaperone activity
Extensive work in recent years has focused on the identiﬁca-
tion and development of small-molecule inhibitors which di-
rectly target speciﬁc HSP family members [37,38]. This
intense area of research has gained momentum as a result of
early indications of success with HSP90 inhibitors. This has
stimulated interest in developing agents which may have eﬃ-
cacy in speciﬁc disease states and in particular oﬀer the poten-
tial for increased therapeutic beneﬁt in the treatment of cancer
through selective eﬀects on tumor versus normal tissues. The
following sections will focus on the progress to date in target-
ing two of the major HSP families, HSP70 and HSP90.3.1. HSP70
The HSP70 family consists of a number of highly conserved
proteins which range in size from 66 kDa to 78 kDa [39]. Gen-
erally, members are structurally similar, comprising an
45 kDa actin-like N-terminal ATPase domain and an
15 kDa substrate-binding domain [39]. An 10 kDa C-termi-
nal domain is the most variable between family members and is
also the position of a C-terminal EEVD motif in the majority
of HSP70 isoforms, which provides the site of interaction with
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[39]. The orchestrated interaction of co-chaperones with
HSP70 ﬁne-tunes the balance of ATP-hydrolysis and nucleo-
tide exchange which are critical for substrate interaction, dic-
tating the duration over which a substrate is associated with
the molecular chaperone (Fig. 2a) [39].
HSP70 chaperones interact with almost all newly synthe-
sized, unfolded proteins [39]. This is achieved by HSP70 bind-
ing to a hydrophobic binding motif which consists of a core of
ﬁve amino acids enriched with hydrophobic residues [38,39].
This binding motif is exposed during protein synthesis; how-
ever, upon protein folding it becomes buried in the hydropho-
bic core of the mature protein only to be re-exposed if the
protein has undergone an unfolding event. Therefore, it is
not surprising that HSP70 chaperones are induced in order
to prevent protein aggregation and facilitate protein re-folding
or degradation in response to stressful stimuli [39]. In addition,
HSP70 chaperones are involved in a number of other cellularFig. 2. The HSP70 chaperone cycle and its modulators. (a) HSP70 in the A
association and dissociation of substrates. HSP40 promotes substrate binding
change which prolongs HSP70 association with substrate. The ADP bound
ATPase domain of HSP70. During nucleotide exchange ATP replaces ADP
mature substrate. HSP70 activity can also be regulated by co-chaperones such
or stimulate nucleotide exchange, respectively (for a comprehensive review see
630668-R/1, both of which modulate HSP70 activity.processes, including transportation of molecules across mem-
branes, disassembly of clathrin-coated vesicles and regulation
of the HSR [39].
HSP70 chaperones are also intricately involved at several
stages in regulating apoptosis [23]. The anti-apoptotic function
of HSP70 chaperones has been reviewed extensively elsewhere
[6,23,40]. Brieﬂy, HSP70 can prevent the loss of mitochondrial
membrane potential in response to apoptotic stimuli and hence
block the release of apoptogenic factors including cytochrome
c and AIF. This has been suggested to be mediated via HSP70
preventing the pro-apoptotic protein BAX from undergoing
the conformational change and translocation to the mitochon-
dria which are essential for its function [41]. HSP70 can also
function downstream of the mitochondria by interacting
directly with APAF-1 or AIF to inhibit their function. In addi-
tion, HSP70 chaperones are potent inhibitors of caspase-inde-
pendent cell death via their modulation of several stages of the
pro-apoptotic JNK pathway [6,23,40].TP-bound form adopts an open conformation which allows the rapid
by stimulating HSP70 ATPase activity. This induces a conformational
form of HSP70 is stabilized by HIP, which interacts directly with the
allowing HSP70 to return to its open conformation and release the
as CHIP and BAG-1 which inhibit HSP40-stimulated ATPase activity
[39]). (b) Chemical structure of 15-DSG and its structural analog NSC-
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which may contribute to tumor initiation and progression.
Many human tumor cells express elevated levels of HSP70
and to some extent the co-chaperone HSP40, suggesting that
cellular transformation causes induction of these chaperone
proteins or conversely that HSP70 may play a role in tumori-
genesis [6,23]. In addition, a number of cancer chemotherapeu-
tic agents, including paclitaxel, doxorubicin and gemcitabine,
have been shown to induce HSP70 expression, resulting in re-
duced cellular sensitivity to these agents [40]. For these rea-
sons, HSP70 has emerged in recent years as a potential new
target for the development of small-molecule inhibitors which
may be used alone or in combination with existing therapeutic
strategies in the treatment of cancer. However, agents which
modulate HSP70 expression and/or activity may also have
scope for the treatment of disease states other than cancer. Be-
cause of their role in nascent protein folding, intracellular
localization and prevention of aggregation, it is not surprising
that the HSP70 family has been implicated in various disease
states which arise due to defects in protein folding or traﬃck-
ing. HSP70 chaperones have been implicated in neurological
conditions including Parkinson’s, Huntington’s and Alzhei-
mer’s disease [3,4,38]. HSP70 and HSP40 chaperones interact
with and modulate the aggregation of a-synuclein and mutant
huntingtin, the proteins implicated in the pathogenesis of Par-
kinson’s and Huntington’s disease, respectively [42,43]. HSP70
isoforms can also interact with amyloid b-peptide and tau
protein, the aberrant aggregation of which is involved in the
development of Alzheimer’s disease [44]. As a consequence,
overexpression of HSP70 and HSP40 has been shown in sev-
eral cellular models of Huntington’s, Parkinson’s and Alzhei-
mer’s disease to have potential therapeutic beneﬁt (reviewed
in [38,39]). HSP70 has also been implicated as a possible ther-
apeutic target for the treatment of cystic ﬁbrosis. This is based
on the role of HSP70 and HSP40 in the biogenesis of the cystic
ﬁbrosis transmembrane conductance regulator (CFTR), the
protein that leads to cystic ﬁbrosis when mutated. Decreased
expression of HSP70 was shown to reduce the association of
HSP70 with mutant CTFR and improve the cellular degrada-
tion of the mutant protein [45].
3.1.1. HSP70-interacting compounds. Considering the pos-
sible therapeutic potential of modulating HSP70 activity, only
a small number of compounds which target HSP70 have been
described so far. One compound, 15-deoxyspergualin (15-
DSG, Fig. 2b), is currently undergoing clinical evaluation as
an immunosuppressive agent and binds to HSC70 (the consti-
tutively expressed isoform of HSP70) with a modest KD of
4lM [46]. 15-DSG mildly stimulates the ATPase activity of
HSC70 by 20–40%, but does not aﬀect synthetic peptide bind-
ing or HSP40-stimulated ATPase activity [46]. This compound
interacts in vitro with the C-terminal EEVD motif of HSC70;
however, it is currently unclear how this interaction modulates
HSC70 ATPase activity [47]. Importantly, 15-DSG also binds
to HSP90 with a similar KD to that for HSC70 [46]. Hence,
given the role of HSP90 in several cellular processes (see
below), it cannot be excluded that 15-DSG may function via
HSP90 rather than HSC70 [38].
With the aim of identifying novel and potentially more po-
tent HSC70 modulators, a large-scale in silico screen of 15-
DSG analogs was conducted [48]. A number of structural
analogs were identiﬁed including NSC-630668-R/1 (R/1,
Fig. 2b), which inhibited the endogenous and HSP40-stimu-lated ATPase activity of yeast HSP70 [48]. As a consequence,
R/1 prevented the translocation of a pre-protein into yeast-de-
rived ER vesicles, an in vitro assay which is dependent on
HSC70 and HSP40 [48]. R/1 may act as a peptide mimetic
by binding to the peptide-binding domain of HSC70 to induce
oligomerization which would eventually lead to its inactivation
[48]. Since the initial identiﬁcation of R/1, several structurally
related compounds have been screened for their ability to alter
the ATPase activity of HSP70 [49]. A number of those identi-
ﬁed were similar to R/1 and stimulated HSP70 ATPase activity
[49]. Interestingly, two novel cell permeable compounds were
recognized which had no eﬀect on the endogenous activity of
HSP70 but instead interfered with the ability of HSP40 to
enhance HSP70-mediated ATP hydrolysis [49]. The two struc-
tural analogs of 15-DSG and R/1, MAL3-39 and MAL3-101,
were also shown to compromise protein translocation into ER
vesicles [49].
HSP70 activity can also be modulated via direct aﬀects on
the ATPase domain. 3 0-Sulfogalactolipids, containing either
a ceramide or a glycerolipid, bind to the ATPase domain of
HSP70 [50]. These compounds inhibit the endogenous and
HSP40-stimulated ATPase cycle of HSP70 chaperones; how-
ever, the functional consequences of this type of inhibition re-
main unclear.
Due to limited availability of small-molecules that inhibit
HSP70 function, the search for peptide aptamers, which can
inhibit the function of this chaperone by acting as a substrate
mimetic, has begun. This is exempliﬁed by ADD70, a con-
struct encoding the minimum region of the HSP70 substrate
AIF (see earlier) required to interact with and thereby capture
endogenous HSP70 [51]. ADD70 when used alone was not
cytotoxic but did display chemosensitizing properties
in vitro and in vivo [51]. In addition, using syngeneic rodent
models, ADD70 was demonstrated to mediate an anti-tumor
eﬀect via a cell–cell speciﬁc immune response mediated by
CD8+ T-cells [51]. Interestingly, ADD70 speciﬁcally inter-
acted with the inducible isoform of HSP70 and not HSC70
[51]. This is of particular importance because the inducible
isoform is often constitutively expressed in cancer cells but
relatively undetectable in the absence of stress in normal cells,
suggesting that this approach may achieve tumor cell versus
normal cell selectivity and hence may have promising thera-
peutic potential [51].
3.2. HSP90
HSP90 is an abundant molecular chaperone which consti-
tutes 1–2% of total cellular protein. It exerts its chaperone
function to ensure the correct conformation, activity, intra-
cellular localization and proteolytic turnover of a range of
proteins that are involved in cell growth, diﬀerentiation
and survival [5,7,37]. Because of the large number of
interesting proteins with which HSP90 has been shown to
associate, a rationale exists for the therapeutic use of
HSP90 inhibitors for the treatment of a wide range of hu-
man diseases [52].
However, HSP90 has probably been most widely acknowl-
edged as a therapeutic target for the treatment of cancer
[5,6]. This is because HSP90 is essential for the stability and
the function of many oncogenic client proteins, which contrib-
ute to all of the hallmark traits of malignancy [6,7,37]. These so
called ‘client proteins’ include ERBB2, BCR-ABL, AKT/PKB,
C-RAF, CDK4, steroid hormone receptors (estrogen and
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http://www.picard.ch/). Inhibition of HSP90 function causes
degradation of client proteins via the ubiquitin–proteasome
pathway, which results in the combinatorial down-regulation
of signals being propagated via numerous signaling pathways
and modulation of all aspects of the malignant phenotype
[5,7,37]. Therefore, HSP90 inhibitors have potential to treat
cancers driven by multiple molecular abnormalities and their
combinatorial eﬀects could also reduce the possibility of resis-
tance developing.
Presently, ﬁve isoforms of HSP90 have been identiﬁed which
diﬀer in their cellular localization. The two major cytoplasmic
isoforms are HSP90a and HSP90b which share approximately
85% sequence identity at the protein level. Other isoforms in-
clude GRP94 in the endoplasmic reticulum, TRAP1 in the
mitochondrial matrix and HSP90N which has been linked to
cellular transformation via its association with RAF [53]. All
isoforms, except HSP90N, have a similar overall structure con-
sisting of three domains: an N-terminal nucleotide exchange
and ATPase domain, a middle domain implicated in client pro-
tein binding, and a C-terminal dimerization domain. They are
considered to exert their chaperone function via a cycle which
utilizes the coordinated interaction of a number of co-chaper-
one proteins that are collectively involved in an orchestrated,
mutually regulatory interplay with ATP/ADP exchange and
ATP hydrolysis by the intrinsic and essential N-terminal ATP-
ase domain (Fig. 3). HSP90N diﬀers from the other HSP90 iso-
forms in that its N-terminal is much shorter than in other
isoforms and as a result does not contain the highly conserved
ATPase domain [54]. In the following sections we discuss the
various classes of HSP90 inhibitors which have emerged in re-Fig. 3. Model of the HSP90 chaperone cycle. The client protein initially bind
bound HSP90 via the TPR co-chaperone HOP. When ADP is exchanged for A
HSP40 and HOP, allowing the ATP-dependent association of other co-chap
compliment depends on the type of client protein. This is collectively referred
active conformation. Other co-chaperones include AHA1 which increases th
formation of the mature complex, resulting in the proteasome-dependent degr
E3 ubiquitin ligase CHIP (reviewed in [93]).cent years and the novel approaches which are currently being
investigated to inhibit HSP90 function.
3.2.1. Natural product inhibitors of HSP90. The 14-mem-
bered macrocyclic antibiotic radicicol (monorden, Fig. 4) was
isolated from Monosporidium bonorden [55]. Radicicol was
demonstrated to have anti-tumor activity in vitro and shown
to reverse the malignant phenotype of v-SRC transformed cells
[56]. Because of this radicicol was originally believed to be a
tyrosine kinase inhibitor; however, it was subsequently shown
using X-ray crystallography to bind to the N-terminal ATP-
binding pocket of HSP90 with high aﬃnity [57], resulting in
the degradation of a number of signaling proteins [58]. Radic-
icol binds to all HSP90 isoforms except for HSP90N [58].
However, the strength of the interaction varies between family
members with radicicol binding to HSP90a and HSP90b with
5- and 10-fold greater aﬃnity than to GRP94 or TRAP1,
respectively [58]. Although radicicol inhibits tumor cell growth
in vitro, it lacks activity in vivo, most likely due to its poten-
tially reactive epoxide moiety and other adverse chemical fea-
tures that cause instability and possible toxicity [37,40]. Many
oxime derivatives of radicicol have been synthesized (including
KF25706 and KF58333) that retain the capacity to inhibit
HSP90 function but also exhibit therapeutic activity in human
tumor xenograft models [59].
The benzoquinone ansamycins are a second class of natu-
rally occurring antibiotics which have been demonstrated to
inhibit the activity of HSP90 (Fig. 4). A leading example is gel-
danamycin which competes with ATP for binding to the N-ter-
minal nucleotide binding site of HSP90 [60]. Geldanamycin
interacts with HSP90a, HSP90b, GRP94 and TRAP1 with
similar aﬃnities [61]. However, despite promising anti-tumors to a HSP70/HSP40 complex which is then transferred onto the ADP-
TP, HSP90 undergoes a conformational change which releases HSP70/
erones including P23, p50CDC37 or the immunophilins (IP). The exact
to as the mature complex and it is here that the client protein adopts its
e ATPase activity of HSP90. Inhibition of ATP-binding prevents the
adation of associated client proteins, possibly via the recruitment of the
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the clinic was stopped due to compound instability and unac-
ceptable hepatotoxicity at therapeutic doses [62].
Further analogs were developed with the objective of ﬁnding
agents with an improved therapeutic window for clinical use,
including the derivative 17-allylamino-17-demethoxygeldana-
mycin (17-AAG or tanespimycin, Fig. 4) [63]. 17-AAG has
similar cellular eﬀects to geldanamycin, including client protein
degradation, cell cycle arrest and apoptosis but with improved
metabolic stability and lower toxicity [7,37]. Preclinical studies
using 17-AAG have shown this derivative to be highly potent
in vitro and to exhibit anti-tumor activity at non-toxic doses in
various human tumor xenograft models [64,65]. The potency
of 17-AAG in vitro has been attributed in part to its increased
uptake and preferential accumulation in cancer cells, together
with enhanced binding to the HSP90 super-chaperone complex
that is reported to predominate in cancer but not normal cells
[66,67]. Based on its biological activity, 17-AAG has recently
completed several phase I clinical trials at numerous centers
in the US and UK. Various dose and scheduling strategies
were examined which have been discussed in detail elsewhere
[52]. Doses of 17-AAG administered were well-tolerated and
resulted in good pharmacokinetic exposures and pharmacody-
namic responses, as demonstrated by the molecular signature
of increased expression of HSP70 and decreased levels of client
proteins C-RAF and CDK4 [68]. Prolonged stable disease in
two patients with metastatic malignant melanoma was re-
ported [68] along with unpublished reports of activity in pros-
tate, breast and multiple myeloma. As a result of favorable
responses during the phase I clinical trial, 17-AAG has now
entered phase II clinical trial for use as a single agent therapy
in various tumor types, including melanoma and breast.Despite promising clinical activity, there are several possible
factors which may reduce the clinical eﬃcacy of 17-AAG.
Preclinical studies have shown that hepatic metabolism of
17-AAG by cytochrome P450 leads to the formation of 17-
amino-17-demethoxygeldanamycin (17-AG) [64]. Although
17-AG retains inhibitory activity, metabolism by CYP3A4 is
likely to be a cause of variable pharmacokinetics. In addition,
the activity of 17-AAG is enhanced by its conversion to the
hydroquinone form, 17-AAGH2, by the reductase enzyme
NQO1 or DT-diaphorase [64,69]. The polymorphic expression
of both of these metabolic enzymes may pose limitations for
the clinical use of 17-AAG across the population [7,37,64].
The eﬃcacy of 17-AAG may be further reduced by its associ-
ation with the multi-drug resistance protein MDR1 or P-glyco-
protein [64]. Finally, 17-AAG is limited by its poor solubility,
cumbersome and complex formulation and lack of oral bio-
availability. Attempts to reformulate 17-AAG have resulted
in clinical trials commencing with CNF1010 (http://www.bio-
genidec.com/) and a cremaphore-based formulation (KOS-
953, http://www.kosan.com/), the latter of which has shown
promising results during the phase I trial in patients with re-
lapsed-refractory myeloma. The US National Cancer Institute
and Kosan Biosciences have also developed a more water
soluble and potentially orally bioavailable analog of 17-
AAG, 17-dimethylaminoethylamino-17-demethoxygeldana-
mycin (17-DMAG or alvespimycin, Fig. 4), which is currently
under preclinical and clinical evaluation [52]. 17-AAGH2, also
known as IPI-504, has also entered clinical trial as a soluble
derivative of 17-AAG [70].
3.2.2. Pyrazole/isoxazole resorcinols. High-throughput
screening at our institution identiﬁed for the ﬁrst time
HSP90 inhibitors with a novel 3,4-diarylpyrazole resorcinol
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CCT018159 (Fig. 4) which inhibits the N-terminal ATPase of
yeast and human HSP90 with an IC50 of 7.1 lM and
3.2 lM, respectively [71]. Treatment of cancer cells with
CCT018159 resulted in HSP70 induction, client protein deple-
tion, cytostasis and apoptosis [71,72]. The pyrazoles have good
solubility and, unlike 17-AAG, the cellular activity of
CCT018159 was shown to be relatively independent of DT-
diaphorase and P-glycoprotein [72]. Building on the X-ray
crystal structure of human HSP90a in a complex with
CCT018159, rational drug design was used by ourselves in col-
laboration with Vernalis to identify structural analogs with en-
hanced, nanomolar potency. This led to the identiﬁcation of
the 5-amide analog CCT0129397/VER-49009 (Fig. 4), which
exhibited similar cellular properties to 17-AAG with the po-
tency and potential for clinical development [73]. The resor-
cinol isoxazole amide analog VER-50589 was recently
reported to be the most potent synthetic small-molecule
HSP90 inhibitor yet identiﬁed (KD 5 nM) and to show proof-
of-concept for in vivo anti-tumor activity in an animal model
[74].
3.2.3. Purines. Rational drug design was used by Chiosis
et al. [75] to develop a novel class of HSP90 inhibitors with
a purine-scaﬀold (Fig. 4). The ﬁrst compound to be identiﬁed
from this series, PU3, bound to HSP90 with moderate aﬃnity
resulting in cellular eﬀects which are characteristic of HSP90
inhibitors [75]. An important feature of PU3 is that it is more
soluble than 17-AAG; however, it is also signiﬁcantly less po-
tent against cells than the ansamycins [75]. Subsequent eﬀorts
focused on improving the potency of PU3 and led to the iden-
tiﬁcation of PU24FCl [76]. This compound exhibited biologi-
cal eﬀects on cells within a concentration range of 2–6 lM
[76], and also demonstrated 10–50 times higher aﬃnity for
HSP90 from transformed cells compared to that from normal
tissues [76]. Administration of PU24FCl in human breast
tumor xenograft models led to anti-tumor activity without sig-
niﬁcant toxicity [76]. A more recent study has identiﬁed 8-aryl-
sulfanyl, 8-arylsulfoxyl and 8-arylsulfonyl adenine
derivatives of the PU class which exhibit improved water sol-
ubility and approximately 50 nM potency in cellular models,
together with therapeutic activity in human tumor xenograft
models [77].
3.2.4. Novobiocin. Novobiocin (Fig. 4) belongs to the fam-
ily of coumarin antibiotics which bind to and inhibit bacterial
DNA gyrase to block bacterial DNA synthesis. This com-
pound is unique because unlike the HSP90 inhibitors described
so far it is believed to inhibit the activity of the chaperone by
interacting with a proposed cryptic ATPase domain within the
C-terminal rather than N-terminal domain of HSP90 [78]. De-
spite the diﬀerent binding site, cells exposed to novobiocin
demonstrated HSP90 inhibition and client protein degradation
in vitro and in vivo [78]. This was subsequently shown to be
due to disruption of the interaction between HSP90 and its
co-chaperones HSC70 and P23 [79]. However, in an eﬀort to
overcome the relative weak ability of novobiocin to inhibit
HSP90 function and induce client protein degradation more
potent analogs have been identiﬁed from a library of structural
derivatives, with the most active being compound 4a (Fig. 4)
[80].
3.2.5. Inhibition of HSP90 using peptide mimetics. She-
pherdin is a novel peptidomimetic modeled on the region
which is critical for the interaction of HSP90 with its anti-apoptotic and mitotic substrate, survivin [81]. Shepherdin
mimics the survivin sequence I74-L87 and makes contact with
the N-terminal ATP-binding pocket of HSP90 to cause inhibi-
tion of chaperone activity, degradation of client proteins and
induction of cell death via apoptotic and non-apoptotic mech-
anisms [81]. Similar to the ansamycin and purine classes of
HSP90 inhibitor, shepherdin showed signiﬁcantly increased
toxicity in tumor cells versus normal cells in vitro. Possible
therapeutic selectivity was supported by in vivo observations
of eﬃcacy without toxicity following systemic administration
using human tumor xenograft models [81]. A recent study
has demonstrated that exposure to shepherdin resulted in dra-
matic cell death of acute myeloid leukemia cells in vitro and in
tumor xenografts by inhibiting HSP90 function, decreasing
HSP90 client proteins and disrupting mitochondrial function
[82].
A novel, non-peptidic small-molecule, 5-aminoimidazole-4-
carboxamide-1-b-D-ribofuranoside (AICAR, Fig. 4), was
designed to bind to HSP90 by mimicking the chemical and
conformation properties of shepherdin bound to the N-termi-
nal domain of HSP90 [83]. AICAR causes client protein degra-
dation in vivo and exhibits anti-proliferative and pro-
apoptotic activity in a number of tumor cell lines, but not
non-tumorigenic cells [83].
3.2.6. Inhibitors of speciﬁc HSP90 isoforms. Speciﬁc iso-
forms of the HSP90 family have been associated with unique
functions and tumor-speciﬁc expression (reviewed in [53]).
Therefore, it may be therapeutically beneﬁcial to target indi-
vidual isoforms of this chaperone family. 5 0-N-ethylcarboxam-
idoadenosine (NECA, Fig. 4) is an example of a compound
which demonstrates selectivity by binding to GRP94 with a
KD of 200 nM [84]. NECA does not bind to the other
HSP90 isoforms and it is currently believed that a ﬁve amino
acid insertion unique to within the N-terminal domain of
GRP94 extends a helix to form an additional pocket adjacent
to the nucleotide binding cavity which allows for this speciﬁc
interaction [85]. Further studies using this compound and
other methods to speciﬁcally reduce individual isoform expres-
sion/activity are required to determine if isoform-selective
inhibitors could be an eﬀective approach to increase therapeu-
tic beneﬁt.
3.2.7. Agents that modulate the post-translational modiﬁca-
tion of HSP90. HSP90 function can be modulated by a series
of post-translational modiﬁcations including acetylation, ubiq-
uitination and S-nitrosylation [37,86]. HSP90 acetylation has
recently been reﬁned to a speciﬁc lysine residue (K294) within
the middle domain of the chaperone [87]. When acetylation of
this residue was mimicked, a substantial decrease in client pro-
tein binding and the association of some but not all co-chaper-
ones was observed [87]. Histone deacetylase (HDAC)
inhibitors have been developed to target epigenetic modiﬁca-
tion of gene transcription through the hyperacetylation of cel-
lular proteins. Following exposure to HDAC inhibitors such
as LAQ824 and depsipeptide FK228, HSP90 becomes acety-
lated which inhibits ATP binding leading to client protein deg-
radation both in vitro and in patients sampled as part of a
Phase I clinical trial [88].
3.2.8. Other HSP90 inhibitors. Mycograb, developed by
NeuTec Pharma Ltd. (http://www.neutecpharma.com/), is a
human recombinant protein which recognizes the middle
domain of fungal HSP90. Clinical data have shown that the
development of HSP90 antibodies is related to patient recovery
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for use in combination with the anti-fungal drug amphotericin
B and clinical trials are currently underway, with preliminary
results indicating an 84% response rate in patients with sys-
temic candidiasis [89]. An application for Mycograb in the
treatment of cancer has been proposed based on the identiﬁca-
tion of HSP90 on the surface of certain cancer cell types
[37,52].
Gene expression-based analysis was used to identify a new
class of HSP90 inhibitor [20]. Using this approach celastrol
and gedunin (described earlier) were shown to have a gene
expression proﬁle similar to that of existing HSP90 inhibitors
[20]. Treatment of cells with celastrol and gedunin resulted in
degradation of HSP90 client proteins including EGFR,
BCR-ABL, androgen receptor and FLT3 [20]. Both celastrol
and gedunin were found to inhibit HSP90 ATPase activity in
the cell [20]. However, unlike the majority of conventional
HSP90 inhibitors, neither of these compounds were found to
interact with the N-terminal ATP-binding pocket of HSP90,
suggesting a novel mode of action [20]. The exact mechanism
of action of celastrol is currently under debate. Previous stud-
ies have shown celastrol to have potent in vitro and in vivo
activity by acting as a proteasome inhibitor [19]. As described
above, HSP90 activity can be modulated by ubiquitination;
therefore, it is necessary to determine if celastrol could be
inhibiting its chaperone function via eﬀects on protein degra-
dation.
3.2.9. Novel approaches to inhibit HSP90 function. So far
this review has focused mainly on inhibiting HSP90 function
by targeting the N-terminal ATPase domain of this chaperone
directly. However, as described earlier, HSP90 functions as
part of a super-chaperone complex which requires the interac-
tion of a number of accessory co-chaperones. An increasing
amount of evidence has emerged concerning the importance
of these co-chaperones and the possibility of targeting
them individually as a novel approach to inhibiting HSP90
function.
One example of an HSP90 co-chaperone is AHA1 (activator
of HSP90 ATPase), which was identiﬁed as a stress-regulated
protein that activates the essential, intrinsic ATPase of
HSP90 to promote client protein maturation [90]. In particu-
lar, v-SRC and glucocorticoid receptor have been shown to
be dependent on AHA1 expression, with their activities being
signiﬁcantly reduced following the reduction of AHA1 expres-
sion using a variety of techniques [91]. In addition, AHA1
plays a critical role in the traﬃcking of the mutant form of
the cystic ﬁbrosis transmembrane conductance regulator,
DF508, with decreased expression of AHA1 resulting in the cell
surface rescue of the protein from the ER [92]. In addition,
data from our own laboratory have shown that reducing the
expression of AHA1 can directly aﬀect the activity of HSP90
as demonstrated by reduced signaling via the RAS-RAF-
MEK-ERK1/2 and PI3K-AKT/PKB pathways (J. Holmes,
S. Sharp and P. Workman, unpublished observations). These
data collectively suggest that AHA1 may be an interesting
drug target with potential inhibitors being used to modulate
speciﬁc activities of HSP90.
HSP70 has already been discussed as another example of a
well-documented HSP90 co-chaperone. HSP70 is involved in
substrate-loading onto HSP90 (Fig. 3). In our laboratory, we
have reduced the expression of HSC70 and HSP72 using an
siRNA approach. This resulted in HSP90 client protein deple-tion, cytostasis and apoptosis in human colon and ovarian cell
lines, the extent of which was greater than observed following
treatment with 17-AAG [7].
AHA1 and HSP70 isoforms are just two examples of co-
chaperones which could potentially be targeted to disrupt
HSP90 function. Our laboratory, and others, are currently
investigating the eﬀects of targeting other co-chaperones
including p50CDC37, P23 and CHIP.4. Combining diﬀerent modulators of the HSR
The therapeutic potential of targeting the HSR may be im-
proved by using more than one agent to speciﬁcally target dif-
ferent aspects of this pathway. For example, a well known
response to HSP90 inhibition is the induction of HSPs,
including HSP90b, HSP72 and HSP27 [16,17]. All three chap-
erones have a well-documented anti-apoptotic function which
may reduce the sensitivity of cells to the cell death eﬀects of
HSP90 inhibitors. In addition, increased expression of the tar-
get itself may contribute to the development of resistance to
these agents [16]. Therefore, it may be of beneﬁt to combine
HSP90 inhibitors with agents which modulate the activity of
these chaperones directly or those which can prevent the
induction of these chaperones, e.g. HSF1 inhibitors. This
has been investigated using siRNA to reduce the expression
of HSP72 prior to treatment with 17-AAG and by the pre-
treatment of cells with the HSF1 inhibitor KNK437 [32].
Both approaches signiﬁcantly enhanced the sensitivity of leu-
kemia cell lines to the eﬀects of HSP90 inhibitors [32]. Simi-
larly, inhibition of HSP72 function by expressing the
peptidomimetic of AIF, ADD70, prior to treatment with
17-AAG has been shown to increase the sensitivity of cancer
cells in vitro and in vivo using syngenic animal models [51].
Finally, preventing the induction of HSP27 using siRNA
techniques has been also shown to increase the sensitivity to
17-AAG and to reverse resistance to this HSP90 inhibitor
[17]. These data collectively suggest that if small-molecule
inhibitors could be designed to modulate diﬀerent aspects of
the HSR, not only may they have therapeutic potential in
their own right, but they might also improve patient response
to existing modulators.5. Concluding remarks
The HSR and the associated molecular players are emerging
as important potential targets for drugs that may be used in
the treatment of cancer and other conditions in which pro-
tein-folding and protein quality control play a key role in dis-
ease pathology. Proof-of-concept for the approach of
modulating protein quality control is provided by the approval
of bortezomib in multiple myeloma [9]. 17-AAG was the ﬁrst
HSP90 molecular chaperone inhibitor to enter clinical trial
and shows early promise as a result of its action on multiple
oncoproteins and all of the hallmark traits of malignancy. This
has generated a high level of interest in industry and academia
to develop additional HSP90 ATPase inhibitors. A number of
these are now entering the clinic or are in late stage preclinical
development, including not only other geldanamycin analogs
but also small-molecule synthetic inhibitors. Pharmacological
agents that interfere with the HSR through other mechanisms
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grab, which recognizes fungal HSP90, shows promise in the
treatment of systemic candidiasis and may also have potential
in cancer. Given the alternative molecular approaches that
could potentially be used to tackle HSP90 and other molecular
chaperones, and considering the number of potential diseases
in which therapeutic modulation of the HSR, molecular chap-
erones and protein folding is indicated, this area looks set to be
a very exciting one over the next few years.
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